Global Anti-Depressants Drugs Market Report 2022 to 2030

Global Anti-Depressants Drugs Market Analysis

$ 3999

The global Anti-Depressants drugs market size was valued at $16.44Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $26 Bn in 2030. drug class, indication, route of administration, end-user, distribution channel and geography. The global Anti-Depressants drug market will grow because of the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies. The key market players are H. Lundbeck A/S (DNK), GlaxoSmithKline plc (GBR), Eli Lilly and Company (USA), Janssen Pharmaceuticals (BEL), Pfizer Inc. (USA), AstraZeneca (GBR), Bristol-Myers Squibb (USA), and others.

ID: IN10GLPH051 CATEGORY: Pharmaceuticals GEOGRAPHY: Global AUTHOR: Chandani Patel

Buy Now

Global Anti-Depressants Drugs Market Executive Summary

The global Anti-Depressants drugs market size was valued at $16.44 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $26 Bn in 2030. Depression is a common mental health disorder characterized by persistent feelings of sadness, loss of interest or pleasure, changes in appetite and sleep patterns, low energy, and difficulty in concentrating. Depression can have a significant impact on an individual's daily life, including their ability to work, socialize, and function in relationships.

According to the World Health Organization (WHO), mental health expenditure is a crucial aspect of the healthcare system, as it determines the availability, accessibility, and quality of mental health services. The WHO recommends that countries allocate at least 5% of their healthcare budget to mental health, but many countries fall short of this target. Global mental health expenditure varies widely across countries and regions. In low-income countries, mental health expenditure is often very low, with many countries spending less than 1% of their healthcare budget on mental health. In contrast, high-income countries tend to spend more on mental health, with some countries spending over 10% of their healthcare budget on mental health.

The prevalence and incidence of depression vary depending on the region, age, gender, and other demographic factors. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting over 264 Mn people globally. Depression is one of the most common mental health disorders globally, with an estimated 4.4% of the world's population experiencing depression at any given time.

The incidence of depression is highest among young adults, with an estimated 15% of people experiencing depression at some point during their lifetime. Depression is more common among women than men. According to the WHO, the prevalence of depression in women is nearly twice as high as in men. The highest rates of depression are found in the Eastern Mediterranean and Western Pacific regions, while the lowest rates are found in the African region. Depression can have a significant impact on an individual's quality of life, leading to disability, loss of productivity, and increased healthcare costs. It is estimated that depression and anxiety disorders cost the global economy over $1 trillion annually.

One of the primary treatments for depression is the use of antidepressant medications, which are drugs that help regulate mood and reduce symptoms of depression. The market for antidepressant drugs has been growing steadily over the years, driven by the increasing prevalence of depression and the rising demand for effective treatments. The impact of depression on the antidepressant drugs market is significant. As the prevalence of depression continues to increase, the demand for antidepressant drugs is expected to grow. In addition, the growing awareness about mental health issues and the availability of effective treatments are also driving market growth.

global anti depressants drugs market

Market Dynamics

Market Growth Drivers Analysis

The antidepressant drugs market is primarily driven by the increasing prevalence of depression and other mental health disorders globally. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting over 264 million people globally. As a result, there is a growing demand for effective treatments, including antidepressant drugs, to manage the symptoms of depression. The rising awareness about mental health issues and the availability of effective treatments are also driving the market growth.

In addition, the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies are also driving the growth of the market. The increasing investment in research and development activities, the emergence of personalized medicine, and the growing trend of combination therapies are expected to create new growth opportunities for the market.

Market Restraints

There are many market restraints as well one of them is the increasing availability of generic versions of antidepressant drugs. Generic drugs are cheaper than branded drugs, which can reduce the overall revenue generated by the market. In addition, the potential side effects of antidepressant drugs, including weight gain, nausea, and dizziness, can affect patient compliance and adherence to treatment.

Moreover, the stringent regulatory requirements for the approval of antidepressant drugs can also pose a challenge to market growth. The complex and time-consuming clinical trials, high development costs, and increasing regulatory scrutiny can delay the approval and launch of new antidepressant drugs.

Competitive Landscape

Key Players

H. Lundbeck A/S (DNK)
GlaxoSmithKline plc (GBR)
Eli Lilly and Company (USA)
Janssen Pharmaceuticals (BEL)
Pfizer Inc. (USA)
AstraZeneca (GBR)
Bristol-Myers Squibb (USA)
Teva Pharmaceutical Industries Ltd. (ISR)
Mallinckrodt (GBR.)
Sun Pharmaceutical Industries Ltd. (IND)
Novartis AG (CHE)
Endo Pharmaceuticals plc (GBR)
Zydus Cadila (IND)
Mylan N.V. (USA.)
Mayne Pharma Group Limited (AUS)
Amneal Pharmaceutical Inc (USA)
Avet Pharmaceuticals Inc. (USA)
Aurobindo Pharma (IND)
WOCKHARDT (IND)
Currax Pharmaceuticals LLC (IND)

Recent developments

June 2021: An agreement to jointly develop and market zuranolone (SAGE-217), which is intended for major depressive disorder, postpartum depression, and other psychiatric illnesses, was made public by Sage Therapeutics and Biogen Inc.

February 2021: On-demand mental healthcare provider Ginger recently announced a cooperation with online pharmacy Capsule. This collaboration sought to deliver anti-depressants and other mental health prescriptions to Ginger members at their homes.

November 2020: Biogen Inc and Sage Therapeutics announced a collaboration agreement to develop and commercialize zuranolone (SAGE-217) indicated for major depressive disorder, postpartum depression and other psychiatric disorders.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Regulations regarding the development, approval, and use of antidepressant drugs differ across the globe, as each country has its own regulatory framework for pharmaceutical products. Here are some examples of the regulatory agencies and guidelines for antidepressant drugs in different regions.

United States:

The Food and Drug Administration (FDA) regulates the approval and marketing of antidepressant drugs in the United States. The FDA requires that all new drugs undergo rigorous clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The FDA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

In the United States, most antidepressant drugs are covered by private insurance plans and government programs such as Medicare and Medicaid. The extent of coverage and cost-sharing requirements may vary depending on the specific insurance plan or program.

European Union:

The European Medicines Agency (EMA) is responsible for the evaluation and approval of antidepressant drugs in the European Union. The EMA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The EMA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

In the European Union, reimbursement policies for antidepressant drugs vary by country. Most European countries have a national healthcare system that covers the cost of antidepressant drugs for eligible patients. However, the specific reimbursement policies and cost-sharing requirements may vary depending on the country.

Japan:

The Pharmaceuticals and Medical Devices Agency (PMDA) regulates the approval and marketing of antidepressant drugs in Japan. The PMDA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The PMDA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

China:

The National Medical Products Administration (NMPA) regulates the approval and marketing of antidepressant drugs in China. The NMPA requires that all new drugs undergo clinical trials to demonstrate their safety and efficacy before they can be approved for marketing. The NMPA also requires that antidepressant drug labels include warnings about potential side effects, including the risk of suicidal thoughts and behavior.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Depressants Drugs Market Segmentation

Drug Class

The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.

Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
Others

Indication

By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.

Major Depressive Disorder
Anxiety Disorders
Attention Deficit Hyperactivity Disorder
Others

Route of Administration

Based on the route of administration the market is segmented into:

Oral
Injectable
Others

End-Users

Based on end users the market is segmented into:

Hospitals
Homecare
Speciality Centres
Others

Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.